Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: What do we know so far?

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Morscio, J ^a   Dierickx, D ^b   Tousseyn, T ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; B LYMPHOCYTE DIFFERENTIATION FACTOR; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAUNORUBICIN; EPSTEIN BARR VIRUS ANTIGEN 2; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 10; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MYC PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN KINASE PIM 1; PROTEIN P21; RITUXIMAB; STAT1 PROTEIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR PAX5; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE SULFATE; TUMOR PROTEIN;

B CELL POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; COPY NUMBER VARIATION; CYTOTOXIC T LYMPHOCYTE; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART LUNG TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; UNIPARENTAL DISOMY; VIRUS LOAD; B LYMPHOCYTE; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC HETEROGENEITY; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MUTATION; ORGAN TRANSPLANTATION; PATHOLOGY; EPSTEIN-BARR VIRUS INFECTIONS; LYMPHOPROLIFERATIVE DISORDERS;

B-LYMPHOCYTES; DNA COPY NUMBER VARIATIONS; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION; GENETIC HETEROGENEITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; MUTATION; NEOPLASM PROTEINS; ORGAN TRANSPLANTATION; TRANSLOCATION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84877262588     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/150835     Document Type: Review

References (142)

1. Dierickx D., Tousseyn T., Sagaert X., Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinico-pathological characteristics and prognostic factors. Leukemia and Lymphoma 2013 10.3109/10428194.2013.780655
2. Herreman A., Dierickx D., Morscio J., Clinicopathological characteristics of Posttransplant Lymphoproliferative Disorders of T-cell origin: single center series of 9 cases and meta-analysis of 147 reported cases. Leukemia and Lymphoma 2013 10.3109/10428194.2013.775436
3. Capello D., Gaidano G., Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease. Mediterranean Journal of Hematology and Infectious Diseases 2009 1 2 e2009018 10.4084/MJHID.2009.018
4. Manez R., Breinig M. C., Linden P., Wilson J., Torre-Cisneros J., Kusne S., Dummer S., Ho M., Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. Journal of Infectious Diseases 1997 176 6 1462 1467 2-s2.0-0030699421 (Pubitemid 27518144)
5. Jox A., Rohen C., Belge G., Bartnitzke S., Pawlita M., Diehl V., Bullerdiek J., Wolf J., Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability. Annals of Oncology 1997 8 2 S131 S135 2-s2.0-0030744016 (Pubitemid 27286889)
6. Morscio J., Dierickx D., Ferreiro J. F., Herreman A., van Loo P., Bittoun E., Gene expression profiling reveals clear differences between EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. American Journal of Transplantation, artnr AJT-O-12-01471, 2013
7. Opelz G., Henderson R., Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. The Lancet 1993 342 8886-8887 1514 1516 2-s2.0-0027501649 10.1016/S0140-6736(05)80084-4 (Pubitemid 23362168)
8. Alizadeh A. A., Elsen M. B., Davis R. E., Ma C. L., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Marü G. E., Moore T., Hudson J., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Levy R., Wilson W., Grever M. R., Byrd J. C., Botstein D., Brown P. O., Staudt L. M., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403 6769 503 511 2-s2.0-0034598746 10.1038/35000501 (Pubitemid 30082188)
9. Capello D., Rossi D., Gaidano G., Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematological Oncology 2005 23 2 61 67 2-s2.0-28844462295 10.1002/hon.751 (Pubitemid 41774988)
10. Johnson L. R., Nalesnik M. A., Swerdlow S. H., Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. American Journal of Surgical Pathology 2006 30 12 1604 1612 2-s2.0-33751338237 10.1097/01.pas.0000213317.59176.d2 (Pubitemid 44808798)
11. Green M., Soltys K., Rowe D. T., Webber S. A., Mazareigos G., Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatric Transplantation 2009 13 3 319 323 2-s2.0-64149112298 10.1111/j.1399-3046.2008.00926.x
12. Schaffer K., Hassan J., Staines A., Surveillance of Epstein-Barr virus loads in adult liver transplantation: associations with age, sex, posttransplant times, and transplant indications. Liver Transplantation 2011 17 12 1420 1426 10.1002/lt.22406
13. Shapiro R. S., McCLain K., Frizzera G., Gajl-Peczalska K. J., Kersey J. H., Blazar B. R., Arthur D. C., Patton D. F., Greenberg J. S., Burke B., Ramsay N. K. C., McGlave P., Filipovich A. H., Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988 71 5 1234 1243 2-s2.0-0023946601
14. Dharnidharka V. R., Dharnidharka V. R., Green M., Webber S. A., Epidemiology of PTLD. Post-Transplant Lymphoproliferative Disorders 2010 New York, NY, USA Springer
15. Ibrahim H. A., Naresh K. N., Posttransplant lymphoproliferative disorders. Advances in Hematology 2012 2012 11 230173 10.1155/2012/230173
16. Murukesan V., Mukherjee S., Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens. Drugs 2012 72 12 1631 1643 10.2165/11635690-000000000-00000
17. Nourse J. P., Jones K., Gandhi M. K., Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. American Journal of Transplantation 2011 11 5 888 895 2-s2.0-79955537371 10.1111/j.1600-6143.2011.03499.x
18. LaCasce A. S., Post-transplant lymphoproliferative disorders. Oncologist 2006 11 6 674 680 2-s2.0-33745647836 10.1634/theoncologist.11-6-674 (Pubitemid 43967622)
19. Curtis R. E., Travis L. B., Rowlings P. A., Socié G., Kingma D. W., Banks P. M., Jaffe E. S., Sale G. E., Horowitz M. M., Witherspoon R. P., Shriner D. A., Weisdorf D. J., Kolb H. J., Sullivan K. M., Sobocinski K. A., Gale R. P., Hoover R. N., Fraumeni J. F., Deeg H. J., Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999 94 7 2208 2216 2-s2.0-0033214901 (Pubitemid 29467666)
20. Lucas K. G., Small T. N., Heller G., Dupont B., O'Reilly R. J., The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996 87 6 2594 2603 2-s2.0-0029915469 (Pubitemid 26086907)
21. Poirel H. A., Bernheim A., Schneider A., Meddeb M., Choquet S., Leblond V., Charlotte F., Davi F., Canioni D., Macintyre E., Mamzer-Bruneel M. F., Hirsch I., Hermine O., Martin A., Cornillet-Lefebvre P., Patey M., Toupance O., Kémény J. L., Deteix P., Raphaël M., Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Transplantation 2005 80 2 176 184 2-s2.0-23044507998 10.1097/01.TP.0000163288.98419.0D (Pubitemid 41061673)
22. Capello D., Rasi S., Oreste P., Veronese S., Cerri M., Ravelli E., Rossi D., Minola E., Colosimo A., Gambacorta M., Muti G., Morra E., Gaidano G., Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. The Journal of Pathology 2009 218 4 478 486 2-s2.0-67650911314 10.1002/path.2555
23. Weissmann D. J., Ferry J. A., Harris N. L., Louis D. N., Delmonico F., Spiro I., Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. American Journal of Clinical Pathology 1995 103 6 748 755 2-s2.0-0029031757
24. Quinlan S. C., Pfeiffer R. M., Morton L. M., Engels E. A., Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. American Journal of Hematology 2011 86 2 206 209 2-s2.0-78851471706 10.1002/ajh.21911
25. Leblond V., Dhedin N., Bruneel M. F. M., Choquet S., Hermine O., Porcher R., Qouc S. N., Davi F., Charlotte F., Dorent R., Borrou B., Vernant J. P., Raphael M., Levy V., Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. Journal of Clinical Oncology 2001 19 3 772 778 2-s2.0-0035253727 (Pubitemid 32119092)
26. Jain A., Nalesnik M., Reyes J., Pokharna R., Mazariegos G., Green M., Eghtesad B., Marsh W., Cacciarelli T., Fontes P., Abu-Elmagd K., Sindhi R., Demetris J., Fung J., Russell P. S., Bartlett S. T., Najarian J. S., Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Annals of Surgery 2002 236 4 429 437 2-s2.0-0036786654 10.1097/00000658-200210000-00005
27. Mucha K., Foroncewicz B., Ziarkiewicz-Wróblewska B., Krawczyk M., Lerut J., Pczek L., Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrology Dialysis Transplantation 2010 25 7 2089 2098 2-s2.0-77954344943 10.1093/ndt/gfq231
28. Domingo-Domenech E., de Sanjose S., Gonzalez-Barca E., Post-transplant lymphomas: a 20-year epidemiologic, clinical and pathologic study in a single center. Haematologica 2001 86 7 715 721 (Pubitemid 32680997)
29. Oton A., Wang H., Leleu X., Melhem M., George D., Lacasce A., Foon K., Ghobrial I., Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leukemia and Lymphoma 2008 49 9 1738 1744 2-s2.0-52349110709 10.1080/10428190802239162
30. Swerdlow S. H., Campo E., Harris N. L., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 Lyon, France IARC Press
31. Cesarman E., Chadburn A., Liu Y. F., Migliazza A., Dalla-Favera R., Knowles D. M., BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998 92 7 2294 2302 2-s2.0-0032189676 (Pubitemid 28452970)
32. Shaknovich R., Basso K., Bhagat G., Mansukhani M., Hatzivassiliou G., Murty V. V., Buettner M., Niedobitek G., Alobeid B., Cattoretti G., Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica 2006 91 10 1313 1320 2-s2.0-33750010591 (Pubitemid 44569803)
33. Jagadeesh D., Woda B. A., Draper J., Evens A. M., Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Current Treatment Options in Oncology 2012 13 1 122 136
34. Evens A. M., Roy R., Sterrenberg D., Moll M. Z., Chadburn A., Gordon L. I., Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Current Oncology Reports 2010 12 6 383 394 2-s2.0-78649905197 10.1007/s11912-010-0132-1
35. Vakiani E., Nandula S. V., Subramaniyam S., Keller C. E., Alobeid B., Murty V. V., Bhagat G., Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Human Pathology 2007 38 2 315 325 2-s2.0-33846192859 10.1016/j.humpath.2006.08.014 (Pubitemid 46096557)
36. Nalesnik M. A., The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transplant Infectious Disease 2001 3 2 88 96 2-s2.0-0035017112 10.1034/j.1399-3062.2001.003002088.x (Pubitemid 32452923)
37. Thorley-Lawson D. A., EBV the prototypical human tumor virus-just how bad is it? Journal of Allergy and Clinical Immunology 2005 116 2 251 261 2-s2.0-23244448471 10.1016/j.jaci.2005.05.038 (Pubitemid 41096526)
38. Thorley-Lawson D. A., Epstein-Barr virus: exploiting the immune system. Nature Reviews Immunology 2001 1 1 75 82 2-s2.0-0035496101 (Pubitemid 33741978)
39. da Silva S. R., de Oliveira D. E., HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Letters 2011 305 2 175 185 2-s2.0-79955473602 10.1016/j.canlet.2011.02.007
40. Hamilton-Dutoit S. J., Rea D., Raphael M., Sandvej K., Delecluse H. J., Gisselbrecht C., Marelle L., Van Krieken J. H. J. M., Pallesen G., Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma: correlation of lymphoma phenotype with three distinct patterns of viral latency. American Journal of Pathology 1993 143 4 1072 1085 2-s2.0-0027848541 (Pubitemid 24070550)
41. Ocheni S., Olusina D. B., Oyekunle A. A., Ibegbulam O. G., Kröger N., Bacher U., Zander A. R., EBV-associated malignancies. Open Infectious Diseases Journal 2010 4 1 101 112 2-s2.0-78249245430 10.2174/1874279301004020101
42. Takacs M., Banati F., Koroknai A., Segesdi J., Salamon D., Wolf H., Niller H. H., Minarovits J., Epigenetic regulation of latent Epstein-Barr virus promoters. Biochimica et Biophysica Acta 2009 1799 3-4 228 235 2-s2.0-77949333092 10.1016/j.bbagrm.2009.10.005
43. Pagès F., Galon J., Karaschuk G., Dudziak D., Camus M., Lazar V., Camilleri-Broët S., Lagorce-Pagès C., Lebel-Binay S., Laux G., Fridman W. H., Henglein B., Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood 2005 105 4 1632 1639 2-s2.0-13544272582 10.1182/blood-2004-08-3196 (Pubitemid 40223684)
44. +-associated posttransplant lymphoproliferative disease: role of interferon- γ American Journal of Transplantation 2009 9 10 2292 2302 2-s2.0-70349212426 10.1111/j.1600-6143.2009. 02781.x
45. Hopwood P., Crawford D. H., The role of EBV in post-transplant malignancies: a review. Journal of Clinical Pathology 2000 53 4 248 254 2-s2.0-0034070035 10.1136/jcp.53.4.248 (Pubitemid 30180395)
46. Thorley-Lawson D. A., Gross A., Persistence of the Epstein-Barr virus and the origins of associated lymphomas. The New England Journal of Medicine 2004 350 13 1328 1337 2-s2.0-1642334164 10.1056/NEJMra032015 (Pubitemid 38375368)
47. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 2-s2.0-0347444723 10.1016/S0092-8674(04)00045-5 (Pubitemid 38167318)
48. Rezk S. A., Weiss L. M., Epstein-Barr virus-associated lymphoproliferative disorders. Human Pathology 2007 38 9 1293 1304 2-s2.0-34547838182 10.1016/j.humpath.2007.05.020 (Pubitemid 47247493)
49. Thompson M. P., Kurzrock R., Epstein-Barr virus and cancer. Clinical Cancer Research 2004 10 3 803 821 2-s2.0-1042301963 10.1158/1078-0432.CCR-0670-3 (Pubitemid 38198878)
50. Swaminathan S., Noncoding RNAs produced by oncogenic human herpesviruses. Journal of Cellular Physiology 2008 216 2 321 326 2-s2.0-46049121347 10.1002/jcp.21480 (Pubitemid 351898457)
51. Samanta M., Iwakiri D., Takada K., Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene 2008 27 30 4150 4160 2-s2.0-47049129929 10.1038/onc.2008.75 (Pubitemid 351969916)
52. Takada K., Role of Epstein-Barr virus in Burkitt's lymphoma. Current Topics in Microbiology and Immunology 2001 258 141 151 2-s2.0-0034966681 (Pubitemid 32574038)
53. Edwards R. H., Marquitz A. R., Raab-Traub N., Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. Journal of Virology 2008 82 18 9094 9106 2-s2.0-50949104366 10.1128/JVI.00785-08
54. Barth S., Meister G., Grasser F. A., EBV-encoded miRNAs. Biochimica et Biophysica Acta 2011 1809 11-12 631 640
55. Zomer A., Vendrig T., Hopmans E. S., van Eijndhoven M., Middeldorp J. M., Pegtel D. M., Exosomes: fit to deliver small RNA. Communicative & Integrative Biology 2010 3 5 447 450
56. Cameron J. E., Yin Q., Fewell C., Lacey M., McBride J., Wang X., Lin Z., Schaefer B. C., Flemington E. K., Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways. Journal of Virology 2008 82 4 1946 1958 2-s2.0-38849160013 10.1128/JVI.02136-07 (Pubitemid 351206940)
57. Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., Croce C. M., Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E()-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2006 103 18 7024 7029 2-s2.0-33646471662 10.1073/pnas.0602266103
58. Craig F. E., Johnson L. R., Harvey S. A. K., Nalesnik M. A., Luo J. H., Bhattacharya S. D., Swerdlow S. H., Gene expression profiling of epstein-barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagnostic Molecular Pathology 2007 16 3 158 168 2-s2.0-34548251516 10.1097/PDM.0b013e31804f54a9 (Pubitemid 47329876)
59. Vakiani E., Basso K., Klein U., Mansukhani M. M., Narayan G., Smith P. M., Murty V. V., Dalla-Favera R., Pasqualucci L., Bhagat G., Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematological Oncology 2008 26 4 199 211 2-s2.0-58949083257 10.1002/hon.859
60. Djokic M., Le Beau M. M., Swinnen L. J., Smith S. M., Rubin C. M., Anastasi J., Carlson K. M., Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes and Cancer 2006 45 3 313 318 2-s2.0-32544436112 10.1002/gcc.20287 (Pubitemid 43238481)
61. Cerri M., Capello D., Muti G., Rambaldi A., Paulli M., Gloghini A., Berra E., Deambrogi C., Rossi D., Franceschetti S., Conconi A., Morra E., Pasqualucci L., Carbone A., Gaidano G., Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. British Journal of Haematology 2004 127 3 362 364 2-s2.0-7944233445 10.1111/j.1365-2141.2004.05203.x (Pubitemid 39468954)
62. 6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. British Journal of Haematology 2003 123 3 475 478 2-s2.0-0242361132 10.1046/j.1365-2141.2003.04644. x (Pubitemid 37363490)
63. Küppers R., B cells under influence: transformation of B cells by Epstein-Barr virus. Nature Reviews Immunology 2003 3 10 801 812 2-s2.0-0142197627 (Pubitemid 37328658)
64. Rinaldi A., Kwee I., Poretti G., Mensah A., Pruneri G., Capello D., Rossi D., Zucca E., Ponzoni M., Catapano C., Tibiletti M. G., Paulli M., Gaidano G., Bertoni F., Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. British Journal of Haematology 2006 134 1 27 36 2-s2.0-33744805413 10.1111/j.1365-2141. 2006.06114.x (Pubitemid 43830024)
65. Rinaldi A., Capello D., Scandurra M., Greiner T. C., Chan W. C., Bhagat G., Rossi D., Morra E., Paulli M., Rambaldi A., Rancoita P. M. V., Inghirami G., Ponzoni M., Moreno S. M., Piris M. A., Mian M., Chigrinova E., Zucca E., Favera R. D., Gaidano G., Kwee I., Bertoni F., Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. British Journal of Haematology 2010 149 4 569 577 2-s2.0-77951672229 10.1111/j.1365-2141.2010.08125.x
66. Cigudosa J. C., Parsa N. Z., Louie D. C., Filippa D. A., Jhanwar S. C., Johansson B., Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes, Chromosomes & Cancer 1999 25 2 123 133 (Pubitemid 29226595)
67. Luo W. J., Takakuwa T., Ham M. F., Wada N., Liu A., Fujita S., Sakane-Ishikawa E., Aozasa K., Epstein-Barr virus is integrated between REL and BCL-11A in American Burkitt lymphoma cell line (NAB-2). Laboratory Investigation 2004 84 9 1193 1199 2-s2.0-4344659497 10.1038/labinvest.3700152 (Pubitemid 39128264)
68. Adams J., Williams S. V., Aveyard J. S., Knowles M. A., Loss of heterozygosity analysis and DNA copy number measurement on 8 p in bladder cancer reveals two mechanisms of allelic loss. Cancer Research 2005 65 1 66 75 2-s2.0-11244266433 (Pubitemid 40070796)
69. Idbaih A., Ducray F., Dehais C., SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PloS ONE 2012 7 10 e45950 10.1371/journal.pone.0045950
70. Abkevich V., Timms K. M., Hennessy B. T., Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. British Journal of Cancer 2012 107 10 1776 1782
71. Matsuse M., Sasaki K., Nishihara E., Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups. PloS ONE 2012 7 4 e36063 10.1371/journal.pone.0036063
72. Saeki H., Kitao H., Yoshinaga K., Nakanoko T., Kubo N., Kakeji Y., Morita M., Maehara Y., Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clinical Cancer Research 2011 17 7 1731 1740 2-s2.0-79953294169 10.1158/1078-0432.CCR-10-1996
73. Middeldorp A., van Eijk R., Oosting J., Increased frequency of 20 q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. International Journal of Cancer 2012 130 4 837 846
74. Booman M., Douwes J., Glas A. M., Riemersma S. A., Jordanova E. S., Kok K., Rosenwald A., de Jong D., Schuuring E., Kluin P. M., Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clinical Cancer Research 2006 12 9 2698 2705 2-s2.0-33646719056 10.1158/1078-0432.CCR-05-2617
75. Duval A., Raphael M., Brennetot C., Poirel H., Buhard O., Aubry A., Martin A., Krimi A., Leblond V., Gabarre J., Davi F., Charlotte F., Berger F., Gaidano G., Capello D., Canioni D., Bordessoule D., Feuillard J., Gaulard P., Delfau M. H., Ferlicot S., Eclache V., Prevot S., Guettier C., Lefevre P. C., Adotti F., Hamelin R., The mutator pathway is a feature of immunodeficiency- related lymphomas. Proceedings of the National Academy of Sciences of the United States of America 2004 101 14 5002 5007 2-s2.0-11144354723 10.1073/pnas. 0400945101 (Pubitemid 38469192)
76. Küppers R., Somatic hypermutation and B cell receptor selection in normal and transformed human B cells. Annals of the New York Academy of Sciences 2003 987 173 179 2-s2.0-0038240920 (Pubitemid 36584020)
77. Pasqualucci L., Neumeister P., Goossens T., Nanjangud G., Chaganti R. S. K., Küppers R., Dalla-Favera R., Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001 412 6844 341 346 2-s2.0-0035913362 10.1038/35085588 (Pubitemid 32691848)
78. Dolcetti R., B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmunity Reviews 2007 7 2 96 101 2-s2.0-36148981135 10.1016/j.autrev.2007.02.012 (Pubitemid 350116719)
79. Kasztelewicz B., Jankowska I., Pawlowska J., Teisseyre J., Dzierzanowska-Fangrat K., The impact of cytokine gene polymorphisms on Epstein-Barr virus infection outcome in pediatric liver transplant recipients. Journal of Clinical Virology 2012 55 3 226 232
80. Lee T. C., Savoldo B., Barshes N. R., Rooney C. M., Heslop H. E., Gee A. P., Caldwell Y., Scott J. D., Goss J. A., Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clinical Transplantation 2006 20 3 389 393 2-s2.0-33745083737 10.1111/j.1399-0012.2006. 00498.x (Pubitemid 43880577)
81. Vanbuskirk A. M., Malik V., Xia D., Pelletier R. P., A gene polymorphism associated with posttransplant lymphoproliferative disorder. Transplantation Proceedings 2001 33 1-2 1834 2-s2.0-0035080994 10.1016/S0041-1345(00)02700-7 (Pubitemid 32238084)
82. McAulay K. A., Haque T., Crawford D. H., Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. British Journal of Cancer 2009 101 6 1019 1027 2-s2.0-70249095988 10.1038/sj.bjc.6605278
83. Udalova I. A., Richardson A., Denys A., Smith C., Ackerman H., Foxwell B., Kwiatkowski D., Functional consequences of a polymorphism affecting NF- B p50-p50 binding to the TNF promoter region. Molecular and Cellular Biology 2000 20 24 9113 9119 2-s2.0-0034459681 10.1128/MCB.20.24.9113-9119.2000 (Pubitemid 32246100)
84. Reshef R., Luskin M. R., Kamoun M., Vardhanabhuti S., Tomaszewski J. E., Stadtmauer E. A., Porter D. L., Heitjan D. F., Tsai D. E., Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. American Journal of Transplantation 2011 11 4 817 825 2-s2.0-79953236786 10.1111/j.1600-6143.2011.03454.x
85. Spink C. F., Keen L. J., Mensah F. K., Law G. R., Bidwell J. L., Morgan G. J., Association between non-Hodgkin lymphoma and haplotypes in the TNF region. British Journal of Haematology 2006 133 3 293 300 2-s2.0-33645459776 10.1111/j.1365-2141.2006.06030.x
86. Babel N., Vergopoulos A., Trappe R. U., Oertel S., Hammer M. H., Karaivanov S., Schneider N., Riess H., Papp-Vary M., Neuhaus R., Gondek L. P., Volk H. D., Reinke P., Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 2007 84 3 387 391 2-s2.0-34547865361 10.1097/01.tp.0000269617. 60751.c4 (Pubitemid 47258328)
87. Hjalgrim H., Rostgaard K., Johnson P. C. D., Shield L., Little A. M., Ekstrom-Smedby K., Adami H. O., Glimelius B., Hamilton-Dutoit S., Kane E., Malcolm Taylor G., McConnachie A., Ryder L. P., Sundstrom C., Andersen P. S., Chang E. T., Alexander F. E., Melbye M., Jarrett R. F., HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2010 107 14 6400 6405 2-s2.0-77950902491 10.1073/pnas.0915054107
88. Ioannidis J. P. A., Skolnik P. R., Chalmers T. C., Lau J., Human leukocyte antigen associations of epidemic Kaposi's sarcoma. AIDS 1995 9 6 649 651 2-s2.0-0029062031
89. Subklewe M., Marquis R., Choquet S., Leblond V., Garnier J. L., Hetzer R., Swinnen L. J., Oertel S., Papp-Vary M., Gonzalez-Barca E., Hepkema B. G., Schoenemann C., May J., Pezzutto A., Riess H., Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 2006 82 8 1093 1100 2-s2.0-33750298690 10.1097/01.tp.0000235889.05171.12 (Pubitemid 44632126)
90. Pourfarziani V., Einollahi B., Taheri S., Nemati E., Nafar M., Kalantar E., Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Annals of Transplantation 2007 12 4 16 22 2-s2.0-46749090582
91. Stern M., Opelz G., Döhler B., Hess C., Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood 2010 115 19 3960 3965 2-s2.0-77952993021 10.1182/blood-2009-10-250134
92. Kasztelewicz B., Jankowska I., Pawlowska J., Teisseyre J., Dzierzanowska-Fangrat K., Epstein-Barr virus gene expression and latent membrane protein 1 gene polymorphism in pediatric liver transplant recipients. Journal of Medical Virology 2011 83 12 2182 2190
93. Johnson R. J., Stack M., Hazlewood S. A., Jones M., Blackmore C. G., Hu L. F., Rowe M., The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. Journal of Virology 1998 72 5 4038 4048 2-s2.0-0031957012 (Pubitemid 28188708)
94. Srivastava G., Wong K. Y., Chiang A. K. S., Lam K. Y., Tao Q., Coinfection of multiple strains of Epstein-Barr virus in immunocompetent normal individuals: reassessment of the viral carrier state. Blood 2000 95 7 2443 2445 2-s2.0-0034177537 (Pubitemid 30167749)
95. Chen H. L., Lung M. L., Chan K. H., Griffin B. E., Ng M. H., Tissue distribution of Epstein-Barr virus genotypes. Journal of Virology 1996 70 10 7301 7305 2-s2.0-0029846923 (Pubitemid 26307457)
96. Buck M., Cross S., Krauer K., Kienzle N., Sculley T. B., A-type and B-type Epstein-Barr virus differ in their ability to spontaneously enter the lytic cycle. Journal of General Virology 1999 80 2 441 445 2-s2.0-0033043358 (Pubitemid 29095206)
97. Lin J. C., Lin S. C., De B. K., Chan W. P., Evatt B. L., Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A virus associated with Hodgkin's disease. Blood 1993 81 12 3372 3381 2-s2.0-0027265209 (Pubitemid 23172923)
98. Sample J., Young L., Martin B., Chatman T., Kieff E., Rickinson A., Kieff E., Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. Journal of Virology 1990 64 9 4084 4092 2-s2.0-0025075748 (Pubitemid 20279813)
99. Amon W., Farrell P. J., Reactivation of Epstein-Barr virus from latency. Reviews in Medical Virology 2005 15 3 149 156 2-s2.0-18744390485 10.1002/rmv.456 (Pubitemid 40675906)
100. Gutiérrez M. I., Ibrahim M. M., Dale J. K., Greiner T. C., Straus S. E., Bhatia K., Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein-Barr virus. Journal of the National Cancer Institute 2002 94 23 1757 1763 2-s2.0-0037021668 (Pubitemid 36004352)
101. Ibrahim H. A. H., Menasce L. P., Pomplun S., Burke M., Bower M., Naresh K. N., Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell Lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)-late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV. European Journal of Haematology 2010 85 3 227 230 2-s2.0-77955780214 10.1111/j.1600-0609.2010.01460.x
102. Rossi D., Capello D., Gloghini A., Franceschetti S., Paulli M., Bhatia K., Saglio G., Vitolo U., Pileri S. A., Esteller M., Carbone A., Gaidano G., Deambrogi C., Berra E., Cerri M., Conconi A., Vendramin C., Gutierrez M., Botto B., Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 2004 89 2 154 164 2-s2.0-2942572047 (Pubitemid 38796489)
103. Leonard S., Wei W., Anderton J., Vockerodt M., Rowe M., Murray P. G., Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin's lymphoma. Journal of Virology 2011 85 18 9568 9577
104. Shaknovich R., Cerchietti L., Tsikitas L., DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood 2011 118 13 3559 3569
105. Alsayed Y., Leleu X., Leontovich A., Oton A. B., Melhem M., George D., Ghobrial I. M., Proteomics analysis in post-transplant lymphoproliferative disorders. European Journal of Haematology 2008 81 4 298 303 2-s2.0-51649128367 10.1111/j.1600-0609.2008.01106.x
106. El-Salem M., Raghunath P. N., Marzec M., Wlodarski P., Tsai D., Hsi E., Wasik M. A., Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Laboratory Investigation 2007 87 1 29 39 2-s2.0-33845775754 10.1038/labinvest.3700494 (Pubitemid 44973651)
107. Pĩon J. D., Labi V., Egle A., Villunger A., Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2008 27 supplement 1 S41 S52 2-s2.0-68149105937 10.1038/onc.2009.42
108. Ghigna M. R., Reineke T., Rince P., Epstein-barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders. Pathobiology 2013 80 2 53 59
109. Badoual C., Hans S., Merillon N., PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV associated head and neck cancer. Cancer Research 2012 73 1 128 138
110. Simpson K. D., Templeton D. J., Cross J. V., Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. Journal of Immunology 2012 189 12 5533 5540
111. Kuppers R., Engert A., Hansmann M. L., Hodgkin lymphoma. The Journal of Clinical Investigation 2012 122 10 3439 3447
112. Kridel R., Sehn L. H., Gascoyne R. D., Pathogenesis of follicular lymphoma. The Journal of Clinical Investigation 2012 122 10 3424 3431
113. Zhang L., Yang J., Qian J., Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 2012 120 18 3783 3792
114. Richendollar B. G., Tsao R. E., Elson P., Jin T., Steinle R., Pohlman B., Hsi E. D., Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leukemia and Lymphoma 2009 50 12 2005 2012 2-s2.0-72949111821 10.3109/10428190903315713
115. Perera S. M., Thomas J. A., Burke M., Crawford D. H., Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. The Journal of Pathology 1998 184 177 184 (Pubitemid 28088426)
116. Verdonk R. C., Haagsma E. B., Jonker M. R., Bok L. I. H., Zandvoort J. H., Kleibeuker J. H., Faber K. N., Dijkstra G., Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients. Inflammatory Bowel Diseases 2007 13 6 703 709 2-s2.0-34250311983 10.1002/ibd.20087 (Pubitemid 46909984)
117. Martorelli D., Muraro E., Merlo A., Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders. Clinical and Developmental Immunology 2012 2012 19 931952 10.1155/2012/931952
118. Ibrahim H. A. H., Menasce L., Pomplun S., Burke M., Bower M., Naresh K. N., Tumour infiltrating plasmacytoid dendritic cells in B cell post-transplant lymphoproliferative disorders, human immunodeficiency virus-associated B cell lymphomas and immune competent diffuse large B cell lymphomas. Histopathology 2011 59 1 152 156 2-s2.0-79960463577 10.1111/j.1365-2559.2011.03872.x
119. Vallhov H., Gutzeit C., Johansson S. M., Nagy N., Paul M., Li Q., Friend S., George T. C., Klein E., Scheynius A., Gabrielsson S., Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. Journal of Immunology 2011 186 1 73 82 2-s2.0-79251581240 10.4049/jimmunol.1001145
120. Birkeland S. A., Bendtzen K., Møller B., Hamilton-Dutoit S., Andersen H. K., Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999 67 6 876 881 2-s2.0-0033608771 (Pubitemid 29169134)
121. Muti G., Klersy C., Baldanti F., Granata S., Oreste P., Pezzetti L., Gatti M., Gargantini L., Caramella M., Mancini V., Gerna G., Morra E., Epstein-barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. British Journal of Haematology 2003 122 6 927 933 2-s2.0-0141428884 10.1046/j.1365-2141.2003.04540. x (Pubitemid 37174613)
122. Lan Q., Zheng T., Rothman N., Zhang Y., Wang S. S., Shen M., Berndt S. I., Zahm S. H., Holford T. R., Leaderer B., Yeager M., Welch R., Boyle P., Zhang B., Zou K., Zhu Y., Chanock S., Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006 107 10 4101 4108 2-s2.0-33646566836 10.1182/blood-2005-10-4160 (Pubitemid 43726819)
123. Nalesnik M. A., Zeevi A., Randhawa P. S., Faro A., Spichty K. J., Demetris A. J., Fung J. J., Whiteside T. L., Starzl T. E., Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clinical Transplantation 1999 13 1 I 39 44 2-s2.0-0033025683 (Pubitemid 29110387)
124. Kosmidis M., Dziunycz P., Suarez-Farinas M., Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients. Journal of Immunotherapy 2010 33 5 538 546
125. Savard M., Bélanger C., Tardif M., Gourde P., Flamand L., Gosselin J., Infection of primary human monocytes by Epstein-Barr virus. Journal of Virology 2000 74 6 2612 2619 2-s2.0-0343775822 10.1128/JVI.74.6.2612-2619.2000 (Pubitemid 30117570)
126. Shimakage M., Kimura M., Yanoma S., Ibe M., Yokota S., Tsujino G., Kozuka T., Dezawa T., Tamura S., Ohshima A., Yutsudo M., Hakura A., Expression of latent and replicative-infection genes of Epstein-Barr virus in macrophage. Archives of Virology 1999 144 1 157 166 2-s2.0-0032898132 10.1007/s007050050492 (Pubitemid 29054108)
127. Croft M., Activation of naive, memory and effector T cells. Current Opinion in Immunology 1994 6 3 431 437 2-s2.0-0028365580 10.1016/0952-7915(94) 90123-6 (Pubitemid 24188493)
128. Salek-Ardakani S., Arrand J. R., Mackett M., Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: Implications for immune evasion by EBV. Virology 2002 304 2 342 351 2-s2.0-0036934980 10.1006/viro.2002.1716 (Pubitemid 36069174)
129. Haddad E., Paczesny S., Leblond V., Seigneurin J. M., Stern M., Achkar A., Bauwens M., Delwail V., Debray D., Duvoux C., Hubert P., Hurault De Ligny B., Wijdenes J., Durandy A., Fischer A., Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001 97 6 1590 1597 2-s2.0-0035869536 10.1182/blood.V97.6.1590 (Pubitemid 32217222)
130. Hinrichs C., Wendland S., Zimmermann H., IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transplant International 2011 24 9 892 903
131. Oertel S. H., Riess H., Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results in Cancer Research 2002 159 89 95 2-s2.0-0036356223
132. Perrine S. P., Hermine O., Small T., Suarez F., O'Reilly R., Boulad F., Fingeroth J., Askin M., Levy A., Mentzer S. J., Di Nicola M., Gianni A. M., Klein C., Horwitz S., Faller D. V., A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007 109 6 2571 2578 2-s2.0-33947275876 10.1182/blood-2006- 01-024703 (Pubitemid 46425904)
133. Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., Rosato A., The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010 95 10 1769 1777 2-s2.0-77957305114 10.3324/haematol.2010.023689
134. Miles J. J., Silins S. L., Burrows S. R., Engineered T cell receptors and their potential in molecular medicine. Current Medicinal Chemistry 2006 13 23 2725 2736 2-s2.0-33749434105 10.2174/092986706778521959 (Pubitemid 44509720)
135. Till B. G., Press O. W., Treatment of lymphoma with adoptively transferred T cells. Expert Opinion on Biological Therapy 2009 9 11 1407 1425 2-s2.0-70350686498 10.1517/14712590903260785
136. Kennedy-Nasser A. A., Bollard C. M., Heslop H. E., Immunotherapy for Epstein-Barr Virus-related lymphomas. Mediterranean Journal of Hematology and Infectious Diseases 2009 1 2 e2009010 10.4084/MJHID.2009.010
137. Davis C. L., Wood B. L., Sabath D. E., Joseph J. S., Stehman-Breen C., Broudy V. C., Interferon- α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998 66 12 1770 1779 2-s2.0-0032573751 10.1097/00007890- 199812270-00035 (Pubitemid 29035007)
138. Kahan B. D., Yakupoglu Y. K., Schoenberg L., Knight R. J., Katz S. M., Lai D., Van Buren C. T., Low incidence of malignancy among sirolimus/ cyclosporine-treated renal transplant recipients. Transplantation 2005 80 6 749 758 2-s2.0-26644443399 10.1097/01.TP.0000173770.42403.F7 (Pubitemid 41443756)
139. Boratyńska M., Watorek E., Smolska D., Patrzałek D., Klinger M., Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplantation Proceedings 2007 39 9 2736 2739 2-s2.0-36048952768 10.1016/j.transproceed.2007.08.078 (Pubitemid 350088107)
140. Mathew T., Kreis H., Friend P., Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clinical Transplantation 2004 18 4 446 449 2-s2.0-4043142865 10.1111/j.1399-0012.2004.00188.x (Pubitemid 39077081)
141. Ramachandiran S., Cain J., Liao A., The Smac mimetic RMT5265 · 2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leukemia Research 2012 36 6 784 790
142. Hui E. P., Taylor G. S., Jia H., Phase 1 trial of recombinant Modified Vaccinia Ankara (MVA) encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Research 2013 10.1158/0008-5472.CAN- 12-2448